Fight CRC Clinical Trial Finder
| NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT03488953 |
TitleLiving Donor Liver Transplantation With Two Stage Hepatectomy for Patients With Isolated, Irresectable Colorectal Liver Metastases | Phase
Not Applicable
|
Date Added 2018-04-05 |
Location
Germany
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03476681 |
TitleStudy of NEO-201 in Solid Tumors Expansion Cohorts | Phase
Phase 1, Phase 2
|
Date Added 2018-03-26 |
Location
Maryland, United States
Virginia, United States |
Prior IO Allowed Yes |
CRC-directed No |
Status
Recruiting
|
Drugs
NEO-201 in combination with pembrolizumab |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03475004 |
TitleStudy of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer | Phase
Phase 2
|
Date Added 2018-03-23 |
Location
Colorado, United States
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Pembrolizumab, Bevacizumab, and Binimetinib |
Tags
MSS/ MMRp
|
| NCT ID NCT03412877 |
TitleAdministration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer | Phase
Phase 2
|
Date Added 2018-01-29 |
Location
Maryland, United States
|
Prior IO Allowed Yes |
CRC-directed No |
Status
Recruiting
|
Drugs
Aldesleukin, Cyclophosphamide, Fludarabine, Individual Patient TCR-Transduced PBL, Pembrolizumab (Keytruda) |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03400332 |
TitleA Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers | Phase
Phase 2
|
Date Added 2018-01-17 |
Location
Arkansas, United States
California, United States Colorado, United States Georgia, United States Maryland, United States Massachusetts, United States Michigan, United States Nebraska, United States Nevada, United States New Jersey, United States New York, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Carolina, United States Texas, United States Utah, United States Virginia, United States Australia Belgium Canada France Germany Italy Poland Spain Sweden Switzerland United Kingdom |
Prior IO Allowed No |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
BMS-986253, Ipilimumab, Nivolumab |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03388632 |
TitleRecombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers | Phase
Phase 1
|
Date Added 2018-01-03 |
Location
Maryland, United States
|
Prior IO Allowed Yes |
CRC-directed No |
Status
Recruiting
|
Drugs
Ipilimumab, Nivolumab, rhIL-15, Opdivo, Yervoy |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03388190 |
TitleMETIMMOX: Colorectal Cancer METastasis – Shaping Anti-tumor IMMunity by OXaliplatin | Phase
Phase 2
|
Date Added 2018-01-02 |
Location
Norway
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
FLOX, Nivolumab, Opdivo |
Tags
MSS/ MMRp
|
| NCT ID NCT03368963 |
TitleTAS102 in Combination With NAL-IRI in Advanced GI Cancers | Phase
Phase 1, Phase 2
|
Date Added 2017-12-11 |
Location
Georgia, United States
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Nanoliposomal Irinotecan, Trifluridine and Tipiracil Hydrochloride |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03366155 |
TitleHepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver | Phase
Phase 2
|
Date Added 2017-12-08 |
Location
Maryland, United States
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
5FU, cetuximab, FUDR-Dex, Irinotecan, Medtronic SynchroMed II Pump with Codman 3000 Constant Flow Pump Catheter, OneRNA, oxaliplatin, panitumumab |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03365882 |
TitleS1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery | Phase
Phase 2
|
Date Added 2017-12-07 |
Location
Alaska, United States
Arizona, United States Arkansas, United States California, United States Colorado, United States Connecticut, United States Florida, United States Georgia, United States Hawaii, United States Idaho, United States Illinois, United States Indiana, United States Iowa, United States Kansas, United States Kentucky, United States Louisiana, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Mississippi, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New Hampshire, United States New Jersey, United States New Mexico, United States North Carolina, United States North Dakota, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Rhode Island, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Vermont, United States Washington, United States West Virginia, United States Wisconsin, United States Wyoming, United States Puerto Rico |
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
cetuximab, HER-2 testing, Irinotecan Hydrochloride, Pertuzumab, Trastuzumab, Camptosar, Erbitux, Herceptin, Perjeta |
Tags
MSS/ MMRp
|
